Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction by Baird, Richard et al.
Toxicity associated with capecitabine plus oxaliplatin in
colorectal cancer before and after an institutional policy of
capecitabine dose reduction
R Baird1, A Biondo1, V Chhaya1, J McLachlan1, A Karpathakis1, S Rahman1, Y Barbachano2, D Cunningham1
and I Chau*,1
1Department of Medicine, Royal Marsden Hospital, London & Surrey, UK; 2Department of Clinical Research and Development,
Royal Marsden Hospital, Surrey, UK
BACKGROUND: Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated
with severe toxicities.
METHODS: Following reporting of severe diarrhoea and dehydration with capecitabine 2000mgm–2 per day plus oxaliplatin every
3 weeks (CAPOX 2000) in 2006, we instituted a policy change to reduce capecitabine dose to 1700mgm–2 per day (CAPOX
1700). We undertook a retrospective analysis comparing toxicities encountered before and after this dose change.
RESULTS: Of the 400 patients treated, no significant differences were seen between the CAPOX 2000 and CAPOX 1700 in grades
3 and 4 diarrhoea (21% vs 19%; P¼ 0.80), stomatitis (0% vs 1%; P¼ 0.50) or grades 2–4 hand foot syndrome (16% vs 11%; P¼ 0.18).
Grades 3 and 4 neutropenia (9.5% vs 3.5%; P¼ 0.03) and all grades hyperbilirubinaemia (60% vs 40%; Po0.0001)
were significantly reduced with CAPOX 1700. Rates of hospitalisation due to toxicities were not different between two groups
(13% vs 11%; P¼ 0.53).
CONCLUSIONS: No clinically or statistically significant differences in gastrointestinal toxicities or hospitalisation rate were seen after
reducing our routine capecitabine dose from CAPOX 2000 to CAPOX 1700.
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Capecitabine plus oxaliplatin (CAPOX) is considered to be a
standard treatment option in advanced colorectal cancer (CRC)
(Cassidy et al, 2008) and as adjuvant therapy in colon cancer
(Haller et al, 2010). In its standard dose schedule of capecitabine
2000mgm–2 per day (days 1–14) and oxaliplatin 130mgm–2
(day 1) every 3 weeks (CAPOX 2000), the reported rate of grades 3
and 4 diarrhoea rate was about 20% (Schmoll et al, 2007; Cassidy
et al, 2008; Rothenberg et al, 2008; Haller et al, 2010). This severe
diarrhoea rate further increased when CAPOX 2000 was combined
with cetuximab (Adams et al, 2009). In addition, there might be
regional differences in the tolerability of capecitabine with
gastrointestinal toxicities being worse in the US population
compared with rest of the world (Haller et al, 2008; Hochster
et al, 2008). Herein, we report our experience in CAPOX-
associated toxicity before and after the introduction of our
institutional policy to decrease capecitabine dose from
2000mgm–2 per day (CAPOX 2000) to 1700mgm–2 per day
(CAPOX 1700) when combined with oxaliplatin in the treatment
of CRC.
PATIENTS AND METHODS
This analysis was approved by the Royal Marsden Hospital
Insitutional Review Board (reference number: GI 107). To be
eligible for inclusion into this study, patients were X18 years of
age, had histological diagnosis of colorectal adenocarcinoma and
treated with CAPOX in either (neo)adjuvant or advanced disease
settings with a minimum of one cycle of chemotherapy. The
CAPOX was given as first line treatment for all patients with
advanced disease. During the study period, patients were treated
with neoadjuvant CAPOX in two prospective studies in MRI-
defined high-risk localised rectal cancer (Chau et al, 2006; Chua
et al, 2010). In addition, patients with stage III CRC were treated
with adjuvant CAPOX both within (Haller et al, 2010) or outside
clinical trials.
Following the reporting of high rates of grades 3 and 4 diarrhoea
and dehydration with CAPOX 2000 in the TREE-1 study (Hochster
et al, 2008) and the initial observation of higher grades 3 and 4
diarrhoea in our prospective EXPERT-C study, we instituted a dose
reduction of capecitabine in August 2006 from CAPOX 2000 to
CAPOX 1700. In addition, patients aged X75 were recommended
to have reduced starting dose of 1500mgm–2 per day for CAPOX
2000 and 1300mgm–2 per day for CAPOX 1700.
Patients were identified from our hospital electronic patient
record (EPR) and pharmacy database, which comprised all
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patients who receive treatment at the Royal Marsden Hospital. The
first 200 patients treated with CAPOX before and 200 patients after
our institutional dose change were selected. In our institution,
patients with significant pre-existing neuropathy or renal impair-
ment (creatinine clearance o30mlmin–1) would not receive
CAPOX for CRC.
Details of patients’ demographics, starting dose, dose reduction
and cessation of CAPOX; toxicity including neutropenia, thrombo-
cytopenia, diarrhoea, skin rash, hypersensitivity, lethargy, hand
foot syndrome (HFS), stomatitis, peripheral neuropathy, constipa-
tion, abdominal pain/cramps, chest pain/cardiac events; hospita-
lisation relating to chemotherapy-induced toxicity and deaths
during hospitalisation were collected retrospectively. An estima-
tion of patients’ baseline renal function (estimated glomerular
filtration rate (eGFR)) was performed using serum creatinine,
patient age, gender and race according to the method described by
Levey et al (1999). Serum bilirubin, alanine transferase (ALT) and
alkaline phosphatase during CAPOX treatment were also collected.
However, liver dysfunction might not necessarily be due to CAPOX
treatment, as patients might have baseline dysfunction due to
underlying liver metastases or secondary to concomitant medi-
cations such as antibiotics. All case notes and investigation results
from all patients were available in our hospital EPR system.
Discrepancies were verified with patients’ written notes if
necessary and the database were appended accordingly. All
toxicities were assessed according to the National Cancer Institute
Common Terminology Criteria for Adverse Events version 3.
The primary aim of our study was to compare toxicity, in
particular diarrhoea, in patients receiving CAPOX in our institu-
tion before (pre-2006 CAPOX 2000) and after (post-2006 CAPOX
1700) the dose change in August 2006. Other outcomes of interests
were toxicity-related hospital admissions and proportions of
patients requiring dose reduction or early termination of
treatment.
With 200 patients in each group (400 patients in total), we could
detect a decrease in incidence of grades 3 and 4 diarrhoea from
20% in the pre-2006 CAPOX 2000 group to 10% in the post-2006
CAPOX 1700 group with 80% power, two-sided a¼ 0.05. Propor-
tions of patients were compared using Fisher’s exact test. Mean
length of hospital stay was compared between the two groups
using paired t-test. We performed univariate and multivariate
logistic regression analyses to assess the impact of treatment
groups (CAPOX 2000 vs CAPOX 1700) and other clinical
determinants on incidence of toxicities (diarrhoea, stomatitis,
HFS, neutropenia, elevated bilirubin, ALT and alkaline phospha-
tase). Apart from treatment groups, other clinical factors included
were disease extent (metastatic vs adjuvant), gender (male vs
female), race (white vs non-white), age (o70 vs X70) and renal
function (eGFR470 vs 50–70 vso50mlmin1). The first factor in
each of these categories and CAPOX 2000 were used as control and
their risk ratios (RR) set at 1. RR41 indicated higher incidence of
toxicities. Factors with Po0.05 in the univariate analysis were
entered into the multivariate model.
RESULTS
Between May 2005 and November 2008, 400 patients were included
in this analysis with 200 in the CAPOX 2000 group and 200 in the
CAPOX 1700 group. Table 1 shows baseline characteristics for
patients included in this study. Thirty and 37 patients were aged
over 75 in the CAPOX 2000 and CAPOX 1700 groups, respectively,
and, therefore, had a reduced starting dose. Table 2 shows the
toxicities encountered during CAPOX treatment. There were no
significant differences between CAPOX 2000 and CAPOX 1700 for
grades 3 and 4 diarrhoea (41 out of 200 vs 38 out of 200; P¼ 0.80)
and all grades diarrhoea (117 out of 200 vs 102 out of 200;
P¼ 0.16). There were also no significant differences for grades
3 and 4 stomatitis (0 out of 200 vs 2 out of 200; P¼ 0.50), all grades
stomatitis (27 out of 200 vs 29 out of 200; P¼ 0.89) or grades 2–4
HFS (31 out of 200 vs 21 out of 200; P¼ 0.18). Grades 3 and 4 as
well as all grades neutropenia were significantly reduced with
CAPOX 1700 (P¼ 0.02 and 0.03, respectively) compared
with CAPOX 2000. Furthermore, CAPOX 1700 was associated with
significantly reduced incidence of all grades elevated bilirubin
(Po0.0001) and ALT (P¼ 0.0161). Grades 3 and 4 elevated
bilirubin, ALT and alkaline phosphatase were infrequently
encountered and were not significantly different between CAPOX
2000 and CAPOX 1700.
Although there was no significant difference in the rate of
hospitalisation due to grades 3–4 toxicities (26 out of 200 vs 21 out
of 200; P¼ 0.53), for those patients requiring hospitalisation,
CAPOX 1700 resulted in a longer mean length of hospital stay
compared with CAPOX 2000 (paired t-test; P¼ 0.0021). Table 3
shows these results. The number of cycles of CAPOX treatment was
similar between the two groups with similar numbers of patients
requiring dose reduction in first four cycles as well as those
requiring to terminate treatment before completing four cycles of
treatment.
Table 4 shows the results of the univariate and multivariate
logistic regression analyses to assess the impact of treatment
groups (CAPOX 2000 vs CAPOX 1700) and other clinical
determinants on incidence of toxicities. The CAPOX 1700 was
associated with significantly less neutropenia and liver dysfunction
(elevated serum bilirubin and ALT) on univariate and multivariate
analyses. Interestingly, (neo)adjuvant therapy was generally
associated with higher incidence of toxicities (RR41), although
only statistically significant in elevated ALT. Similarly, females
were associated with higher incidence of toxicities, significantly so
in grades 3 and 4 diarrhoea. The only exception was all grades
elevated bilirubin in which females experienced less toxicities.
Table 1 Baseline characteristics
Pre-2006
CAPOX 2000
Post-2006
CAPOX 1700
N 200 200
Median age (years) (range) 65 (23–83) 66 (23–87)
AgedX75 years 30 (15%)a 37 (19%)b
Aged o75 years 170 (85%) 163 (82%)
Gender
Male 118 (59%) 121 (61%)
Female 82 (41%) 79 (39%)
Race
White 177 (89%) 186 (93%)
Asian 8 (4%) 11 (6%)
Black 11 (6%) 3 (2%)
Others 4 (2%) 0 (0%)
Treatment intention
(Neo)adjuvant 68 (34%) 48 (24%)
Metastatic 132 (66%) 152 (76%)
Baseline eGFR
Median (mlmin – 1) (range) 83 (31–151) 83 (40–214)
o50mlmin – 1 6 (3%) 5 (3%)
50–70mlmin – 1 44 (22%) 49 (25%)
470mlmin – 1 150 (75%) 146 (73%)
Abbreviations: CAPOX¼ capecitabine plus oxaliplatin; eGFR¼ estimated glomerular
filtration rate. This table shows number of patients in each category unless otherwise
stated (i.e. median age and median eGFR). aAged X75 years and had capecitabine
starting dose of 1500mgm– 2 per day instead of 2000mgm–2 per day. bAged X75
years and had capecitabine starting dose of 1300mgm– 2 per day instead of
1700mgm– 2 per day.
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Mild renal impairment (eGFR: 50–70mlmin–1) was associated
with significantly more severe diarrhoea, but not other toxicities.
DISCUSSION
In this retrospective analysis of 400 patients, we did not detect any
differences in the proportion of patients experiencing severe
diarrhoea between CAPOX 2000 and CAPOX 1700 – a major
reason that prompted dose reduction of capecitabine in other
studies. Whereas our cohorts of patients were treated in two
different time periods, the indications for our patients to receive
CAPOX within our institution would be similar. This finding was a
surprise to us as there was a general feeling that CAPOX 2000 was
less tolerable.
One needs to take into account that our cohorts were derived
from routine clinical practice, rather than from a prospective
clinical trial population. The median age in our patient population
was 65 years, comparable with 60–66 years old in other studies
(Diaz-Rubio et al, 2007; Fuchs et al, 2007; Porschen et al, 2007;
Hochster et al, 2008; Haller et al, 2010). Collection of toxicity data
was through medical chart review and thus not as complete
as prospective toxicity data collection. Nevertheless, it would
be unusual for severe (grades 3 and 4) toxicity reporting to
be omitted from the case notes. Similarly, although patients could
have been hospitalised outside our institution, it would be our
routine practice to admit patients into our institution for
chemotherapy-related toxicities. Whereas data on dose reduction
and early termination of treatment were collected in our study, we
did not collect data on dose delay, as a variety of reasons could
contribute to dose delay including patients’ wish or public
holidays, rather than related to toxicity. As our study was
conducted in real life situation, therefore, not to the stringency
of prospective clinical trials, we could not report the dose
intensities in either treatment group (CAPOX 2000 vs CAPOX
1700).
In randomised-controlled trials (RCTs), the rates of diarrhoea
do not differ whether CAPOX was given in the adjuvant or
metastatic disease setting (Schmoll et al, 2007; Cassidy et al, 2008;
Rothenberg et al, 2008; Haller et al, 2010). Table 5 shows grades
3 and 4 toxicities encountered in RCTs evaluating CAPOX (Diaz-
Rubio et al, 2007; Porschen et al, 2007; Cassidy et al, 2008;
Rothenberg et al, 2008; Haller et al, 2010). With CAPOX 2000, the
rates of grades 3 and 4 diarrhoea were about 20% (Cassidy et al,
2008; Rothenberg et al, 2008; Haller et al, 2010). In TREE-1 study,
CAPOX 2000 was associated with grades 3 and 4 diarrhoea in 31%
and dehydration in 27% of patients (Hochster et al, 2008). As a
result, the dose of CAPOX was reduced to 1700mgm–2 per day in
the subsequent cohort when bevacizumab was added to CAPOX.
The efficacy was not compromised with the reduced dose. An
objective response rate of 27% and 46% and median overall
survival of 17.2 and 24.6 months were seen with CAPOX 2000 and
CAPOX 1700 plus bevacizumab, respectively. As no improvement
in response rate or overall survival was observed when bevacizu-
mab was added to CAPOX in a randomised study (Saltz et al,
2008), the numerically better response rate and overall survival
seen in TREE-1 study in CAPOX 1700 plus bevacizumab could not
be accounted for by the addition of bevacizumab. We did not
assess efficacy end points in our study, as patients could be treated
in either (neo)adjuvant or metastatic setting. Furthermore, the
baseline prognostic factor could be variable, for example resectable
metastatic liver only disease vs unresectable widespread metastatic
disease.
Potential regional differences have been reported in the safety
profiles for capecitabine (Haller et al, 2008). Grades 3 and 4
toxicities, in particular gastrointestinal toxicities, were signifi-
cantly more frequent in the United States compared with non-US
population. These toxicities led to significantly more treatment
Table 2 Toxicity and hospitalisation during CAPOX treatment
CAPOX 2000 (n¼ 200) CAPOX 1700 (n¼ 200)
Toxicity G1 G2 G3 G4 G1 G2 G3 G4
Diarrhoea 60 (30%) 16 (8%) 40 (20%) 1 (0.5%) 40 (20%) 24 (12%) 35 (17.5%) 3 (1.5%)
Lethargy 47 (23.5%) 11 (5.5%) 15 (7.5%) 0 (0%) 56 (28%) 34 (17%) 33 (16.5%) 1 (0.5%)
Hand foot syndrome 23 (11.5%) 18 (9%) 13 (6.5%) 0 (0%) 21 (10.5%) 8 (4%) 13 (6.5%) 0 (0%)
Stomatitis 22 (11%) 5 (2.5%) 0 (0%) 0 (0%) 22 (11%) 5 (2.5%) 2 (1%) 0 (0%)
Peripheral neuropathy 97 (48.5%) 16 (8%) 12 (6%) 0 (0%) 109 (54.5%) 24 (12%) 10 (5%) 0 (0%)
Chest paina 0 (0%) 0 (0%) 6 (3%) 0 (0%) 4 (2%) 0 (0%) 4 (2%) 0 (0%)
Laboratory data
Neutropenia 7 (3.5%) 12 (6%) 16 (8%) 3 (1.5%) 7 (3.5%) 8 (4%) 7 (3.5%) 0 (0%)
Elevated bilirubin 77 (38.5%) 37 (18.5%) 5 (2.5%) 0 (0%) 47 (23.5%) 27 (13.5%) 5 (2.5%) 0 (0%)
Elevated ALT 87 (43.5%) 16 (8%) 3 (1.5%) 0 (0%) 55 (27.5%) 21 (10.5%) 5 (2.5%) 0 (0%)
Elevated alkaline phosphatase 63 (31.5%) 12 (6%) 2 (1%) 0 (0%) 77 (38.5%) 11 (10.5%) 4 (2%) 0 (0%)
Hospitalisation rate due to grades 3 out of 4 toxicities
Yes 26 (13%) 21 (10.5%)
No 174 (87%) 179 (89.5%)
Length of hospitalisation
Mean 4.91 days 10.53 days
s.d. 4.73 days 9.99 days
Median 3 days 6.5 days
Range 1–21 days (1–39 days)
Deaths during hospital admission 0 2
Abbreviations: ALT¼ alanine transferase; CAPOX¼ capecitabine plus oxaliplatin; s.d.¼ standard deviation; G¼ grade. aConsidered to be cardiac in origin.
Table 3 Drug delivery during CAPOX treatment
CAPOX 2000 CAPOX 1700
Median number of cycles (range) 7 (1–20) 5 (1–18)
No. of patients with dose reduction in
first four cycles, but continue treatment
60 (30%) 57 (28.5%)
No. of patients who stopped treatment
before cycle four CAPOX
32 (16%) 46 (21.5%)
Abbreviation: CAPOX¼ capecitabine plus oxaliplatin.
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Table 4 Univariate and multivariate analyses of clinical determinants and toxicities
Univariate analyses Multivariate analyses
Clinical factors
No. of
patients
Risk
ratio
95% confidence
interval P
Risk
ratio
95% confidence
interval P
Grades 3 and 4 diarrhoea
Treatment groups
CAPOX 2000 200 1
CAPOX 1700 200 0.88 0.53–1.45 0.61 NA
Disease extent
Metastatic 284 1
(Neo)adjuvant 116 1.65 0.97–2.80 0.07 NA
Gender
Male 239 1 1
Female 161 1.74 1.05–2.90 0.03 1.69 1.01–2.83 0.047
Race
White 363 1
Non-white 37 0.67 0.25–1.77 0.42 NA
Age
o70 years old 262 1
X70 years old 138 0.77 0.44–1.32 0.34 NA
Baseline eGFR
470mlmin – 1 296 1 1
50–70mlmin – 1 93 2.34 1.36–4.03 0.002 2.27 1.31–3.92 0.003
o50mlmin – 1a 11
All grades diarrhoea
Treatment groups
CAPOX 2000 200 1
CAPOX 1700 200 0.74 0.50–1.10 0.13 NA
Disease extent
Metastatic 284 1
(Neo)adjuvant 116 1.31 0.85–2.03 0.23 NA
Gender
Male 239 1
Female 161 1.23 0.82–1.84 0.32 NA
Race
White 363 1
Non-white 37 0.41 0.20–0.84 0.01 NA
Age
o70 years old 262 1
X70 years old 138 1.46 0.96–2.23 0.08 NA
Baseline eGFR
470mlmin – 1 296 1
50–70mlmin – 1 93 1.42 0.88–2.29 0.15 NA
o50mlmin – 1 11 1.08 0.32–3.61 0.90
All grades stomatitis
Treatment groups
CAPOX 2000 200 1
CAPOX 1700 200 1.09 0.62–1.91 0.77 NA
Disease extent
Metastatic 284 1
(Neo)adjuvant 116 1.88 1.05–3.37 0.03 NA
Gender
Male 239 1
Female 161 1.34 0.76–2.37 0.31 NA
Race
White 363 1
Non-white 37 1.05 0.39–2.81 0.93 NA
Age
o70 years old 262 1
X70 years old 138 0.73 0.39–1.35 0.32 NA
Baseline eGFR
470mlmin – 1 296 1
50–70mlmin – 1 93 0.60 0.28–1.28 0.18 NA
o50mlmin – 1 11 1.24 0.26–5.93 0.79
Grades 2–4 hand foot syndrome
Treatment groups
CAPOX 2000 200 1
CAPOX 1700 200 0.64 0.35–1.16 0.14 NA
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Table 4 (Continued )
Univariate analyses Multivariate analyses
Clinical factors
No. of
patients
Risk
ratio
95% confidence
interval P
Risk
ratio
95% confidence
interval P
Disease extent
Metastatic 284 1 1
(Neo)adjuvant 116 2.62 1.44–4.74 0.002 2.52 1.39–4.59 0.002
Gender
Male 239 1
Female 161 1.01 0.56–1.82 0.98 NA
Race
White 363 1
Non-white 37 0.50 0.22–1.16 0.11 NA
Age
o70 years old 262 1 1
X70 years old 138 0.47 0.23–0.94 0.03 0.49 0.24–1.00 0.05
Baseline eGFR
470mlmin – 1 296 1
50–70mlmin – 1 93 1.50 0.79–2.85 0.22 NA
o50mlmin – 1a 11
Grades 3–4 neutropenia
Treatment groups
CAPOX 2000 200 1
CAPOX 1700 200 0.35 0.14–0.84 0.02 NA
Disease extent
Metastatic 284 1
(Neo)adjuvant 116 1.58 0.70–3.59 0.28 NA
Gender
Male 239 1
Female 161 2.13 0.95–4.76 0.07 NA
Race
White 363 1
Non-white 37 1.30 0.37–4.57 0.68 NA
Age
o70 years old 262 1
X70 years old 138 0.68 0.28–1.67 0.40 NA
Baseline eGFR
470mlmin – 1 296 1
50–70mlmin – 1 93 0.74 0.27–2.03 0.56 NA
o50mlmin – 1a 11
All grades neutropenia
Treatment groups
CAPOX 2000 200 1
CAPOX 1700 200 0.53 0.30–0.93 0.03 NA
Disease extent
Metastatic 284 1
(Neo)adjuvant 116 1.39 0.78–2.48 0.27 NA
Gender
Male 239 1
Female 161 1.47 0.85–2.56 0.17 NA
Race
White 363 1
Non-white 37 0.61 0.26–1.40 0.24 NA
Age
o70 years old 262 1
X70 years old 138 0.79 0.43–1.42 0.43 NA
Baseline eGFR
470mlmin – 1 296 1
50–70mlmin – 1 93 0.69 0.34–1.40 0.31 NA
o50mlmin – 1 11 0.52 0.06–4.13 0.53
All grades elevated serum bilirubin
Treatment groups
CAPOX 2000 200 1 1
CAPOX 1700 200 0.44 0.29–0.66 o0.001 0.43 0.29–0.64 o0.001
Disease extent
Metastatic 284 1
(Neo)adjuvant 116 1.02 0.66–1.57 0.92 NA
Gender
Male 239 1 1
Female 161 0.61 0.41–0.91 0.02 0.59 0.39–0.88 0.01
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discontinuation. These findings were seen in both metastatic and
adjuvant disease settings. In the adjuvant CAPOX study, NO16968,
the main differences were between United States and East Asia
with the Europeans having overlapping 95% confidence interval
with the US population in the relative risk of treatment-related
toxicities.
In another UK COIN study, significantly higher rates of grades 3
and 4 diarrhoea were reported when CAPOX 2000 was combined
with cetuximab (17% CAPOX alone vs 30% CAPOX plus
cetuximab; Po0.001) (Adams et al, 2009). As a result, the COIN
Trial Management Group reduced CAPOX 2000 to CAPOX 1700
when combined with cetuximab. After dose reduction, the rates of
grade 3þ diarrhoea decreased from 30% to 16%. The rates of
grade 3þ diarrhoea for CAPOX 2000 without cetuximab in this
COIN trial were 12–17%, as compared with 20% seen in our study
for CAPOX 2000.
We also investigated the relationship between CAPOX dose and
liver dysfunction. As liver dysfunction could be due to underlying
Table 4 (Continued )
Univariate analyses Multivariate analyses
Clinical factors
No. of
patients
Risk
ratio
95% confidence
interval P
Risk
ratio
95% confidence
interval P
Race
White 363 1
Non-white 37 1.08 0.55–2.12 0.83 NA
Age
o70 years old 262 1
X70 years old 138 0.92 0.61–1.39 0.68 NA
Baseline eGFR
470mlmin – 1 296 1
50–70mlmin – 1 93 1.48 0.91–2.32 0.12 NA
o50mlmin – 1 11 0.62 0.18–2.18 0.46
All grades elevated serum ALT
Treatment groups
CAPOX 2000 200 1 1
CAPOX 1700 200 0.60 0.40–0.89 0.01 0.62 0.41–0.93 0.02
Disease extent
Metastatic 284 1 1
(Neo)adjuvant 116 1.77 1.14–2.73 0.01 1.63 1.05–2.54 0.03
Gender
Male 239 1
Female 161 1.43 0.96–2.14 0.08 NA
Race
White 363 1
Non-white 37 0.85 0.43–1.68 0.64 NA
Age
o70 years old 262 1 1
X70 years old 138 0.58 0.38–0.88 0.01 0.58 0.38–0.90 0.01
Baseline eGFR
470mlmin – 1 296 1
50–70mlmin – 1 93 0.91 0.57–1.46 0.70 NA
o50mlmin – 1 11 0.92 0.28–3.09 0.90
All grades elevated serum alkaline phosphatase
Treatment groups
CAPOX 2000 200 1
CAPOX 1700 200 1.35 0.91–2.01 0.14 NA
Disease extent
Metastatic 284 1
(Neo)adjuvant 116 0.43 0.27–0.69 o0.001 NA
Gender
Male 239 1
Female 161 1.23 0.82–1.84 0.32 NA
Race
White 363 1
Non-white 37 0.81 0.41–1.63 0.56 NA
Age
o70 years old 262 1
X70 years old 138 0.72 0.47–1.10 0.13 NA
Baseline eGFR
470mlmin – 1 296 1
50–70mlmin – 1 93 0.80 0.50–1.29 0.36 NA
o50mlmin – 1 11 2.32 0.66–8.08 0.19
Abbreviations: ALT¼ alanine transferase; CAPOX¼ capecitabine plus oxaliplatin; eGFR¼ estimated glomerular filtration rate; NA¼ not applicable. These factors were non-
significant in univariate analyses and, therefore, not entered into multivariate regression models. When less than 2 factors was significant in univariate analyses, no multivariate
analysis was performed. aBaseline eGFR o50mlmin – 1 had too few events in the category to perform meaningful statistical analyses.
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liver metastasis, infection or concomitant medications, not all
toxicities observed were treatment related. However, it was notable
that in the original phase I dose-finding trial for CAPOX, there was
a 33% grades 3 and 4 liver toxicity rate observed in CAPOX 2000,
but there was no grades 3 and 4 liver toxicities encountered in the
dose level below (CAPOX 1650) (Diaz-Rubio et al, 2002). In our
study, CAPOX 1700 was associated with significantly reduced
incidence of elevated bilirubin and ALT. However, most liver
toxicities were of grades 1 and 2, fully reversible and did not
require specific management.
With regard to other clinical factors, which might predict
toxicities in our study, patients treated within the (neo)adjuvant
setting had a general non-significant increase in toxicity in our
univariate analysis. This might reflect clinicians’ reluctance for
dose reduction in this setting, resulting in higher incidence of
toxicities. The only exception was elevated serum alkaline
phosphatase being more frequent in metastatic setting, which
highlighted the underlying liver metastases in these patients.
Females experienced more grades 3 and 4 diarrhoea in our study.
Females have been found to experience greater fluorouracil
toxicity than men with CRC (Sloan et al, 2002) in a meta-analysis
of five RCTs in advanced and adjuvant settings. Women and their
tumours may be more sensitive to 5-FU than men and lower doses
of 5-FU may have an increased pharmacological and antitumour
effect in females. It is well recognised that patients with moderate
renal impairment (creatinine clearance 30–50mlmin–1) would
experience a higher incidence of grade 3 or 4 toxicities (Cassidy
et al, 2002). The phase III data and an additional pharmacokinetic
study support a lower starting dose in these patients. This was
indeed practised in our study patients, although very few (n¼ 11)
patients had eGFR o50mlmin–1. This might explain the
favourable safety seen in this group of patients in our study.
However, published data on mild renal impairment (50–
70mlmin–1) are few. In our study, mild renal impairment was
associated with higher frequency of severe diarrhoea. This was
important as the coupling of diarrhoea with mild renal impairment
could quickly lead to dehydration and acute renal failure.
Thankfully no other toxicities were significantly increased in
patients with mild renal impairment. Furthermore, the reduced
starting dose for our elderly patients again led to favourable safety
profile with no significantly increased toxicities compared with
those younger than 70 years old.
In conclusion, in our cohort of 400 patients, we did not detect
any statistically or clinically significant differences in GI toxicities
or hospitalisation rates after reducing our routine capecitabine
dose from CAPOX 2000 to CAPOX 1700. However, there was
reduced frequency of neutropenia and liver dysfunction with the
use of CAPOX 1700.
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